To our knowledge, this retrospective analysis represents the pioneering effort to investigate the immunophenotype and the impact of integrating immunotherapy with chemotherapy in Chinese patients with BRAF-mutant NSCLC. Here, BRAF is linked to non-small cell lung carcinoma.